Abstract
Currently, immunotherapy holds one of the leading positions in clinical practice. One of the predictive factors is the molecular phenotype of tumors with microsatellite instability features. Clinical trials demonstrate the high effectiveness of checkpoint inhibitors in this subgroup in terms of achieving an objective response, its duration, progression free survival, and overall survival. Such results encourage the use of immunotherapeutic approaches at early stages of the disease with the potential to cure this patient’s population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
